QPPV.COM KNOWLEDGE ASSESSMENT

Nonacog Alfa: Classification, Mechanism, Safety and Pharmacovigilance — Knowledge Assessment

Test your understanding of the concepts covered by Nonacog Alfa: Classification, Mechanism, Safety and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which pharmacovigilance interpretation best reflects the therapeutic role of nonacog alfa?

Only adverse reactions need assessment because efficacy is not a pharmacovigilance concern Clinical benefit and safety must both be assessed because inadequate haemostasis may reflect several causes A reported bleed automatically demonstrates defective product quality Laboratory factor levels are irrelevant if the patient received the labelled dose

Question 2 of 10 Why should inhibitor status be specifically assessed after a hypersensitivity reaction in a patient with haemophilia B?

Factor IX inhibitors are clinically unrelated to hypersensitivity Hypersensitivity in this setting may be associated with factor IX inhibitor development Inhibitor testing is required only when thrombosis occurs A positive inhibitor test proves that the product was contaminated

Question 3 of 10 Why should exact indication be captured in a nonacog alfa safety report?

Prophylaxis, bleeding treatment and surgery involve different exposure patterns and haemostatic expectations The indication determines whether a batch number is required by definition Indication is relevant only for financial reporting All uses have identical dosing, monitoring and clinical interpretation

Question 4 of 10 Which follow-up information would be most useful for characterising a suspected anaphylactic reaction to nonacog alfa?

Only the patient’s age and the product’s marketing authorisation date Timing during infusion, clinical manifestations, previous exposures, inhibitor testing, treatment and rechallenge information Only the patient’s baseline haemoglobin concentration The number of prophylaxis doses prescribed during the previous year, without event timing

Question 5 of 10 A hypersensitivity event occurs shortly after infusion. What is the most appropriate initial product-quality interpretation?

Temporal association alone proves contamination The event should be ignored because it occurred during expected exposure The event should be clinically assessed first, while a manufacturing investigation is considered when case features or clustering support it The batch should automatically be classified as defective

Question 6 of 10 Which data element is especially important when interpreting a measured factor IX activity result?

The patient’s preferred injection site only The timing of the assay relative to the infusion and the assay method The date of the original marketing authorisation only Whether the patient has ever received a non-factor therapy, without any laboratory timing

Question 7 of 10 Which home-treatment event could mimic pharmacological lack of efficacy without representing failure of the factor molecule itself?

Incorrect reconstitution or incomplete transfer of diluent Documented expected factor recovery after infusion Accurate administration with no bleeding A recorded batch number linked to the administered vial

Question 8 of 10 Which set of information is most appropriate for evaluating an unexpected breakthrough bleed during prophylaxis?

Only the patient’s diagnosis and the product name Last prophylactic dose, dose calculation, timing, adherence, factor IX level, inhibitor status and bleeding outcome Only the presence of a product complaint in the same month The patient’s age without treatment or laboratory details

Question 9 of 10 Which statement correctly distinguishes immune-tolerance-associated nephrotic syndrome from routine prophylaxis monitoring?

Nephrotic syndrome is a routine expected outcome of all prophylactic factor IX use Nephrotic syndrome has been reported in haemophilia B patients with inhibitors undergoing immune-tolerance procedures and requires specialist context Nephrotic syndrome confirms product contamination in every case Immune tolerance and routine prophylaxis are interchangeable treatment contexts

Question 10 of 10 Which combination best supports assessment of a thrombotic event reported during nonacog alfa treatment?

Only the presence or absence of a previous allergy Dose, factor IX activity, surgery, central venous access, liver disease, disseminated intravascular coagulation and other risk factors Only the patient’s product preference The batch number without any information about exposure or clinical context

Nonacog Alfa: Classification, Mechanism, Safety and Pharmacovigilance — Knowledge Assessment

Cookie Settings